AVNS · As filed with the SEC
Avanos Medical cash flow statement, by fiscal year
The statement as Avanos Medical presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED CASH FLOW STATEMENTS · USD
| USD | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 |
|---|---|---|---|---|
| Operating Activities | ||||
| Net loss | (72,900,000) | (392,100,000) | (61,800,000) | 50,500,000 |
| Depreciation and amortization | 38,900,000 | 45,500,000 | 46,100,000 | 47,700,000 |
| Stock-based compensation | 12,600,000 | 13,800,000 | 15,800,000 | 15,900,000 |
| Goodwill and intangibles impairment | 77,000,000 | 436,700,000 | — | — |
| Loss on RH disposal | 0 | 0 | 70,800,000 | — |
| Net losses on asset dispositions and asset impairments | — | — | 1,900,000 | 1,100,000 |
| Net losses on asset dispositions and asset impairments | 9,300,000 | 1,200,000 | — | — |
| Changes in operating assets and liabilities, net of acquisition | ||||
| Accounts receivable | 30,900,000 | (6,600,000) | 39,000,000 | (24,700,000) |
| Inventories, net of allowance | 200,000 | 39,000,000 | 4,700,000 | (30,900,000) |
| Prepaid expenses and other assets | 1,400,000 | 14,900,000 | (19,600,000) | 3,000,000 |
| Accounts payable | 600,000 | (900,000) | (14,400,000) | 35,400,000 |
| Accrued expenses | (12,900,000) | (11,400,000) | (27,700,000) | (7,100,000) |
| Deferred income taxes and other | — | — | (22,400,000) | 0 |
| Deferred income taxes and other | (10,400,000) | (39,400,000) | — | — |
| Cash Provided by Operating Activities | 74,700,000 | 100,700,000 | 32,400,000 | 90,900,000 |
| Investing Activities | ||||
| Capital expenditures | (31,600,000) | (17,800,000) | (17,800,000) | (19,300,000) |
| Proceeds from the sale of assets | 4,000,000 | — | — | — |
| Proceeds from the RH divestiture | 0 | 0 | 89,000,000 | — |
| Proceeds from RH divestiture post-closing settlement | 0 | 2,100,000 | — | — |
| Acquisition of assets and businesses, net of cash acquired | (28,000,000) | 0 | (49,600,000) | (116,100,000) |
| Acquisition of minority interest investment | — | — | — | 0 |
| Investments in non-affiliates | (5,000,000) | (11,800,000) | — | — |
| Cash (Used in) Provided by Investing Activities | (60,600,000) | (27,500,000) | 21,600,000 | (135,400,000) |
| Financing Activities | ||||
| Proceeds from issuance of secured debt | — | 0 | 0 | 250,000,000 |
| Secured debt repayments | — | — | (4,700,000) | (126,600,000) |
| Debt issuance costs | — | — | — | (2,900,000) |
| Secured debt repayments | (9,400,000) | (8,600,000) | — | — |
| Debt issuance costs | — | 0 | 0 | — |
| Revolving credit facility proceeds | — | — | 55,000,000 | — |
| Revolving credit facility proceeds | 0 | 20,000,000 | — | 150,000,000 |
| Revolving credit facility repayments | (25,000,000) | (45,000,000) | (115,000,000) | (170,000,000) |
| Purchase of treasury stock | (3,300,000) | (12,800,000) | (19,100,000) | (45,500,000) |
| Proceeds from the exercise of stock options | — | — | 1,300,000 | 1,700,000 |
| Proceeds from the exercise of stock options | 700,000 | 1,100,000 | — | — |
| Payment of contingent consideration liabilities | 0 | (3,800,000) | (11,700,000) | 0 |
| Cash Used in Financing Activities | (37,000,000) | (49,100,000) | (94,200,000) | 56,700,000 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 5,000,000 | (4,100,000) | 200,000 | (3,000,000) |
| (Decrease) Increase in Cash and Cash Equivalents | (17,900,000) | 20,000,000 | (40,000,000) | 9,200,000 |
| Cash and Cash Equivalents - Beginning of Year | 107,700,000 | 87,700,000 | 127,700,000 | 118,500,000 |
| Cash and Cash Equivalents - End of Year | 89,800,000 | 107,700,000 | 87,700,000 | 127,700,000 |
| Supplemental Cash Flow Disclosure: | ||||
| Cash refund for income taxes | — | — | — | (2,900,000) |
| Cash paid for income taxes | 14,100,000 | 3,300,000 | 23,600,000 | — |
| Cash paid for interest | 6,500,000 | 11,500,000 | 14,700,000 | 8,100,000 |
| Supplemental Noncash Disclosure | ||||
| Capital expenditures included in accounts payable or accrued expenses | 1,600,000 | 5,600,000 | 3,400,000 | 3,900,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.